Health Care • Biotechnology: Pharmaceutical Preparations
$37.52 ▲ +0.41
(+1.11%)
MKT CAP: $27.10B • VOL: 3.73M
52W L $19 52W H $43
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$32
MEDIAN
$42
MEAN
$43
HIGH
$51
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ROIV TAPE
ROIV // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $45.40 | $43.15 | 2025-02-14 | $34.14 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $47.28 | $44.27 | 2025-02-06 | $35.27 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $42.77 | $41.27 | 2025-01-29 | $36.02 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $38.27 | — | 2025-01-17 | $36.77 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $33.02 | $35.64 | 2025-01-09 | $33.39 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $44.65 | $39.02 | 2024-12-18 | $32.64 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $36.39 | $37.90 | 2024-12-04 | $34.89 | -4.3% | 48% | C |